newsfilter
← Latest News
GlobeNewswire·

Cidara Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results

Announced expanded and accelerated Phase 3 Plan for CD388, its non-vaccine influenza preventative therapeuticEnrolled and dosed first patients in Phase 3 ANCHOR study; target enrollment on track for completion in the